Zhou, Qing
Zhang, He-Long
Jiang, Li-Yan
Shi, Yuan-Kai
Chen, Yuan
Yu, Jin-Ming
Zhou, Cai-Cun
He, Yong
Hu, Yan-Ping
Liang, Zong-An
Pan, Yue-Yin
Zhuo, Wen-Lei
Song, Yong
Wu, Gang
Chen, Gong-Yan
Lu, You
Zhang, Cui-Ying
Zhang, Yi-Ping
Cheng, Ying
Lu, Shun
Wang, Chang-Li
Zhou, Jian-Ying
Liu, Yun-Peng
He, Jian-Xing
Wang, Jie
Wu, Yi-Long
Clinical trials referenced in this document:
Documents that mention this clinical trial
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study
https://doi.org/10.1007/s00432-023-04923-8
Funding for this research was provided by:
AstraZeneca
Article History
Received: 14 April 2023
Accepted: 23 May 2023
First Online: 14 June 2023
Declarations
:
: QZ reports honoraria from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, and Sanofi. C–C Z reports personal fees from Lily China, Sanofi, BI, Roche China, MSD, Qilu, Hengrui, Innovent Biologics, C-stone, LUYE Pharma, TopAlliance Biosciences Inc, Amoy Diagnostics. SL received research support and speaker fees from AstraZeneca, Hutchison, BMS, Heng Rui, Beigene, Roche, and Hansoh and acted as an advisor and consultant with AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, Simcere, ZaiLab, GenomiCare, Yuhan Corporation, PrIME Oncology, Menarini, and Roche. Y-LW reports advisory services for AstraZeneca, Boehringer Ingelheim, Novartis, Takeda; personal fees from AstraZeneca, Beigene, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, Sanofi; and grants from AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, and Roche. The remaining authors have no conflicts of interest to declare.
: The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, the Declaration of Helsinki, local regulatory requirements, and the policy on bioethics and human biologic samples of AstraZeneca.
: Informed consent was obtained from all the participants included in the study.
: Not applicable.